| Identification | More | [Name]
Ginsenoside Rd | [CAS]
52705-93-8 | [Synonyms]
2-o-beta-d-glucopyranosyl-(3beta,12beta)-20-(beta-d-glucopyranosyloxy)-12-hydroxydammara-24-en-3-yl-beta-d-glucopyranoside
GINSENOSIDE RD
beta-d-glucopyranoside,(3-beta,12-beta)-20-(beta-d-glucopyranosyloxy)-12-hydro
xydammar-24-en-3-yl2-o-beta-d-glucopyranosyl-
Ginsenoside Rd std.
GINSENOOSIDERD
Ginsenoside Rd (CAS# 52705-93-87)
GINSENOSIDE Rd hplc
2-O-beta-D-Glucopyranosyl-(3beta,12beta)-20-(beta-D-glucopyranosyloxy)-12-hydroxydammara-24-en-3-yl-beta-D-glucopyranoside
GINSENOSIDE RD WITH HPLC
glucopyranosyloxy)-12-hydroxydammar-24-en-3-yl2-O-β-D-glucopyranosyl-
β-D-Glucopyranoside,(3β,12β)-20-(β-D-
(20S)-3β-[[2-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl]oxy]-20-(β-D-glucopyranosyloxy)dammaran-24-ene-12β-ol
(20S)-3β-[2-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyloxy]-20-(β-D-glucopyranosyloxy)dammar-24-ene-12β-ol
[20-(β-D-Glucopyranosyloxy)-12β-hydroxydammar-24-en-3β-yl]2-O-β-D-glucopyranosyl-β-D-glucopyranoside
20-(β-D-Glucopyranosyloxy)-12β-hydroxy-5α-dammar-24-ene-3β-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside
3β-[2-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyloxy]-20-(β-D-glucopyranosyloxy)dammar-24-ene-12β-ol | [EINECS(EC#)]
258-118-5 | [Molecular Formula]
C48H82O19 | [MDL Number]
MFCD00210508 | [Molecular Weight]
963.15 | [MOL File]
52705-93-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
204～206℃ | [Boiling point ]
1015.6±65.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.85±0.70(Predicted) | [color ]
White to Off-White | [Detection Methods]
NMR,HPLC | [Stability:]
Hygroscopic | [InChIKey]
FBFMBWCLBGQEBU-FIKSETHBNA-N | [LogP]
3.110 (est) | [CAS DataBase Reference]
52705-93-8(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S2:Keep out of the reach of children .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [WGK Germany ]
3 | [HS Code ]
29389090 |
| Hazard Information | Back Directory | [Description]
Ginsenosides are pharmacologically active natural constituents of ginseng and other plants of the genus Panax.1 Structurally, they are steroid glycosides derived from the triterpene squalene.1 Ginsenoside Rd is a protopanaxadiol which is more abundant in some Panax species (e.g., P. quinquefolium) than others.2 This ginsenoside has diverse in vitro and in vivo effects, including cardioprotective, neuroprotective, and anti-inflammatory actions.3,4,5 Notably, ginsenoside Rd is converted to other ginsenosides in response to steaming or heating plant materials, leading to loss of these activities.2 | [Chemical Properties]
White to off-white crystals powder | [Uses]
Ginsenoside RD has been shown to attenuate tau protein phosphorylation via the PI3K/AKT/GSK-3β pathway after forebrain ischemia. This could be used to counter the risk of developing post-stroke dementia. | [Definition]
ChEBI: Ginsenoside Rd is a ginsenoside found in Panax ginseng and Panax japonicus var. major that is (20S)-ginsenoside Rg3 in which the hydroxy group at position 20 has been converted to its beta-D-glucopyranoside. It has a role as a vulnerary, a neuroprotective agent, an apoptosis inducer, an anti-inflammatory drug, an immunosuppressive agent and a plant metabolite. It is a ginsenoside, a beta-D-glucoside and a tetracyclic triterpenoid. It is functionally related to a (20S)-ginsenoside Rg3. | [in vivo]
Ginsenosides Rd is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Ginsenoside Rd treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/ Ginsenoside Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Ginsenoside Rd treatments[3]. | [IC 50]
NF-κB: 12.05 μM (IC50, in HepG2 cells); COX-2; L-type calcium channel; CYP2D6: 58 μM (IC50); CYP1A2: 78.4 μM (IC50); CYP3A4: 81.7 μM (IC50); CYP2C9: 85.1 μM (IC50) |
|
|